A double-blind, placebo-controlled, first-in-human study to determine safety, tolerability, and pharmacokinetics of JNJ-10450232 (NTM-006) following single and multiple doses in healthy male volunteers
Latest Information Update: 23 Sep 2022
At a glance
- Drugs JNJ 10450232 (Primary)
- Indications Neuropathic pain; Pain; Postoperative pain
- Focus Adverse reactions; First in man; Pharmacokinetics
Most Recent Events
- 01 Oct 2022 Results published in the Regulatory Toxicology and Pharmacology
- 23 Sep 2022 New trial record